E.g., 10/28/2021
E.g., 10/28/2021
Title Category Credit Event date Pricesort ascending
Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Treatment of renal cell carcinoma has changed with expanding indications for Robotic Partial nephrectomy and inclusion of new FDA approved treatments  for advanced RCC.  This course will focus on didactic case discussions using video tape analysis of surgical treatment, setup and successful completion of Robotic Partial nephrectomy, complication management and how to optimize outcomes.  Urologists are now faced with treatment of advanced RCC with a host of options, from tyrosine kinase inhibitors to checkpoint inhibitors.
Trimodality Therapy for Management of Muscle Invasive Bladder Cancer Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course is a comprehensive review of tri-modal therapy for muscularis propria invasive urothelial carcinoma of the bladder with a multidisciplinary faculty including urology, radiation oncology, and medical oncology. We will review results from prospective randomized trials and large institutional experiences in tri-modality bladder sparing therapy. The course will focus on the Urologist's critical role in patient selection for this approach vs. radical cystectomy.
Engaging Disparities in Prostate Cancer Care Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00
Urologic Care for the Advanced Practice Provider Webcast (2020) $0.00 COMPLIMENTARY WEBCAST FOR AUA MEMBERS!
Surgical Management of BPH Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Surgical Management of BPH is an exciting new educational initiative featuring a series of four interactive, case-based, live virtual courses conducted in English, Spanish, Portuguese, and French.  For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion.  Semi-live surgical videos will be utilized to demonstrate and emphasize the significant elements of various BPH procedures.
Metastatic Hormone Sensitive Prostate Cancer: Expert Guidance for Urologists Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 In just the last decade, the FDA has approved several new therapies for the treatment of prostate cancer. It is critical for urologists to understand the sequencing of agents for the treatment of mHSPC because of the overlapping toxicities and the increasing role for treating mHSPC patients. For each new agent, urologists should be able to identify the active agents and their mechanism of action, analyze the breakthrough treatments in the management of advanced and mHSPC, and describe the indications and combinations for treatment with approved agents in the management of mHSPC.
The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Webcast (2021)
    • 3.75 AMA PRA Category 1 Credit™
    • 3.75 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC).
PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. 
Building a Primary Palliative Care Model for Urology Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Building a Primary Palliative Care Model for Urology Webcast (2021) discusses aspects of palliative care that benefit patients, the urologist’s role and their collaboration with palliative care clinicians including:
PARP Inhibitors: Assessing the Clinical Trial Landscape Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. 
Refractory Overactive Bladder: How to Select 3rd Line Therapies and Optimize Outcomes Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Upon completion, participants will be familiar with 3rd line therapies available to treat refractory OAB, including the pros and cons of each option, the current data regarding outcomes to facilitate proper patient counseling, and optimal techniques to maximize the success of the various therapies. The case-based format will provide real-world scenarios by which to learn about the implementation of successful 3rd line options.
PARP Inhibitors: Best Practices in Advanced Prostate Cancer Care in the Community Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00
Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease, & Castration Resistant Prostate...
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g.
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Interdisciplinary review of new and historical systemic treatments for prostate, bladder, and kidney cancer. Concept of IO and CPI will be reviewed. Most recent NCCN guidelines and the studies that shaped these will be reviewed for each tumor type. At the end of the didactic, the audience will be introduced to various cases and asked to respond to best care. 
AUA Guidelines on Advanced/Metastatic/Castration Resistant Prostate Cancer Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course will review the important and newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive (HSPC) and Castration-Resistant Prostate Cancer (CRPC). This includes a thorough discussion of new trials and approval of agents directed at the androgen axis for treatment of M1 HSPC and non-metastatic MO CRPC. Faculty will highlight the management of patients with advanced prostate cancer, including mHSPC, nmCRPC, and CRPC, and how therapeutic options have been incorporated into evidence-based guidelines.

Pages